CLNN Clene Inc

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene to Present at the Canaccord 45th Annual Growth Conference

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings.

Date: August 12th, 2025

Time of Presentation: 3:30pm ET

Location: Boston, MA

Format: Presentation

1x1 Meetings: Please contact your Canaccord representative

A webcast of the presentation will be available on the “” section of the Clene website. Alternatively, one can register online to view the webcast here: .

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit  or follow us on  and .

Investor Contact

Kevin Gardner

LifeSci Advisors

617-283-2856





EN
05/08/2025

Underlying

CLNNClene Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clene Inc

 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene to Present at the Canaccord 45th Annual Growth Conference SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings. Date: August 12th, 2025Time of Presen...

13h / 33m 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Provides Regulatory Update Following Constructive FDA Type-C Mee...

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3rd Quarter of 2025, to discuss ALS survival data and MS clinical development programSubmission of new drug application for ALS under the accelerated a...

June 30, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Reports First Quarter 2025 Financial Results and Recent Operatin...

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and ne...

May 7, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Emerging Growth Conference

Clene to Present at the Emerging Growth Conference SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:00 p.m. EDTFormat: Corporate updat...

April 14, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-...

Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Clene, Inc...

April 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch